Bio-Techne Co. (NASDAQ:TECH) Shares Sold by Wellington Management Group LLP

04 Apr 2025, 06:15 by Doug Wharley · The Cerbat Gem

Wellington Management Group LLP trimmed its position in shares of Bio-Techne Co. (NASDAQ:TECH – Free Report) by 6.1% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,439,313 shares of the biotechnology company’s stock after selling 93,276 shares during the period. Wellington Management Group LLP’s holdings in Bio-Techne were worth $103,674,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in TECH. Norges Bank purchased a new stake in shares of Bio-Techne in the 4th quarter valued at approximately $137,301,000. Raymond James Financial Inc. purchased a new position in Bio-Techne in the fourth quarter valued at $44,479,000. Sumitomo Mitsui Trust Group Inc. raised its stake in Bio-Techne by 21.0% in the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,040,840 shares of the biotechnology company’s stock valued at $147,002,000 after buying an additional 354,478 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Bio-Techne by 1.5% during the 4th quarter. Vanguard Group Inc. now owns 18,594,608 shares of the biotechnology company’s stock worth $1,339,370,000 after buying an additional 275,644 shares during the last quarter. Finally, Proficio Capital Partners LLC boosted its position in shares of Bio-Techne by 8,079.6% during the 4th quarter. Proficio Capital Partners LLC now owns 242,525 shares of the biotechnology company’s stock worth $17,469,000 after acquiring an additional 239,560 shares in the last quarter. Institutional investors and hedge funds own 98.95% of the company’s stock.

Analyst Upgrades and Downgrades

TECH has been the topic of several research analyst reports. Citigroup cut their target price on Bio-Techne from $80.00 to $70.00 and set a “neutral” rating on the stock in a research report on Tuesday, March 4th. Evercore ISI began coverage on shares of Bio-Techne in a research report on Tuesday, March 18th. They set an “outperform” rating and a $75.00 price objective for the company. Robert W. Baird cut shares of Bio-Techne from an “outperform” rating to a “neutral” rating and lowered their target price for the company from $88.00 to $68.00 in a report on Wednesday, February 19th. Royal Bank of Canada boosted their price target on shares of Bio-Techne from $79.00 to $80.00 and gave the company a “sector perform” rating in a research report on Thursday, February 6th. Finally, StockNews.com cut Bio-Techne from a “buy” rating to a “hold” rating in a research report on Wednesday, March 26th. Five equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $81.25.

Check Out Our Latest Stock Report on Bio-Techne

Bio-Techne Stock Performance

Shares of TECH stock opened at $54.86 on Friday. Bio-Techne Co. has a 52-week low of $54.82 and a 52-week high of $85.57. The company has a quick ratio of 2.77, a current ratio of 3.94 and a debt-to-equity ratio of 0.14. The stock’s 50-day moving average price is $64.94 and its 200 day moving average price is $71.01. The stock has a market capitalization of $8.67 billion, a PE ratio of 55.41, a price-to-earnings-growth ratio of 2.88 and a beta of 1.30.

Bio-Techne (NASDAQ:TECH – Get Free Report) last issued its quarterly earnings results on Wednesday, February 5th. The biotechnology company reported $0.35 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.38 by ($0.03). Bio-Techne had a return on equity of 12.73% and a net margin of 13.22%. As a group, equities research analysts forecast that Bio-Techne Co. will post 1.67 EPS for the current year.

Bio-Techne Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, February 28th. Stockholders of record on Monday, February 17th were issued a $0.08 dividend. The ex-dividend date was Friday, February 14th. This represents a $0.32 annualized dividend and a dividend yield of 0.58%. Bio-Techne’s dividend payout ratio is currently 32.32%.

Insider Activity at Bio-Techne

In related news, Director Amy E. Herr sold 1,860 shares of the firm’s stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $65.96, for a total value of $122,685.60. Following the completion of the sale, the director now owns 1,976 shares in the company, valued at $130,336.96. This trade represents a 48.49 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Kim Kelderman sold 13,392 shares of the company’s stock in a transaction dated Monday, January 27th. The stock was sold at an average price of $77.29, for a total transaction of $1,035,067.68. Following the transaction, the chief executive officer now owns 39,004 shares in the company, valued at $3,014,619.16. The trade was a 25.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 3.90% of the company’s stock.

Bio-Techne Company Profile

(Free Report)